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Introduction
The complement system is an important part of the innate immune system, forming an important link with adaptive immune responses [1] , and interacts directly with the haemostatic system [2;3] . It is activated via the classical, alternative and lectin pathways (CP, AP and LP respectively) [4] , which converge at the level of C3. The CP is triggered by antigen-antibody complexes, and the LP by sugars recognised primarily by mannose binding lectin. Following activation of several proteases, a C3 convertase proteolyses C3 into C3a and C3b, the latter forming a C5 convertase. In the AP, C3 is hydrolysed spontaneously and then binds factor B (FB), which is cleaved by factor D to produce fragment Bb and a C3 convertase, with the liberation of fragment C3a [5] . The AP can also be potentiated by plasma kallikrein, which cleaves FB. C3b acts as the central effector molecule in C5 convertase, with cleavage of C5, producing C5a and C5b. The terminal complement complex (TCC, SC5b-9) is generated by the assembly of C5b through C9 and forms the membrane attack complex, mediating the irreversible target cell membrane damage associated with complement activation. The anaphylatoxin C3a has a half-life of several hours, but in serum is cleaved rapidly to the more stable C3a-desArg, which provides a marker of complement activation [6] . C5a and SC5b-9 levels are markers of terminal complement pathway activation [7] [8] [9] . FB is unique to the alternative complement pathway, hence Bb fragment is a marker of AP activation [10] .
Disorders of complement activation or dysregulation can result in excessive complement
generation and thrombosis, such as in paroxysmal nocturnal haemoglobinuria (PNH) [11] , atypical haemolytic uremic syndrome (aHUS) [12] , thrombotic thrombocytopenic purpura (TTP) [13] and antiphospholipid syndrome (APS) [14;15] .
Clinical studies and murine models suggest involvement of the complement system in thrombotic APS. APS patients exhibit low serum complement C3 and C4 levels, with C3a, C3a-desArg and C4a significantly higher than in healthy controls, suggesting that APSassociated hypocomplementemia is due to complement activation rather than complement deficiency [14;16] . The potent inflammatory mediator C5a is implicated in APS, and complement inhibition may ameliorate thrombosis induced by antiphospholipid antibodies (aPL) [17;18] . Mice treated with IgG from APS patients with high levels of aPL, subjected to a femoral vein pinch model of thrombosis, developed larger thrombi and higher TF activity than controls [19] . The co-administration of rEV576 (coversin), a recombinant protein inhibitor of C5 activation, resulted in significantly smaller thrombi and reduced tissue factor (TF) activity [19] . Furthermore, complement activation is a central mechanism in murine aPL-induced pregnancy loss and intrauterine fetal growth restriction [20;21] . Widespread complement activation may also play a role in catastrophic APS (CAPS) (22-24)and anecdotal case reports suggest possible efficacy of eculizumab (Soliris), a humanised monoclonal antibody that inhibits C5 [25;26] .
Limited in vitro data suggest that thrombin, as well as coagulation factors (F) XIa, Xa, IXa, and plasmin, can activate C5 to C5a in the absence of C3 [2] . Complement activation can amplify coagulation and inhibit fibrinolysis, through C5a, which induces expression of TF and plasminogen activator inhibitor 1 (PAI-1) [2] . The anti-complement activation effect of heparin, first described in 1929 by Ecker and Gross [27] , may be through its inhibitory effects on thrombin and FXa, which are known to cause activation of C3 and C5 producing C3a, C5a and subsequently SC5b-9.
We hypothesised that rivaroxaban, as a direct FXa inhibitor has the potential to inhibit FXa induced complement activation of C5 to C5a. The aim of this study was to establish, in patients with APS and previous venous thromboembolism (VTE), whether rivaroxaban administration limits complement activation compared to warfarin, the current mainstay of anticoagulation in this patient group. IgG and IgM anticardiolipin (aCL) and anti-β2 glycoprotein I (aβ2GPI) antibodies were assessed by ELISA (Quanta Lite, Inova, Werfen). Moderate/high aCL positivity was defined as >20 GPLU/MPLU, and aβ2GPI positivity as >20 SGu/SMu.
Patients and methods

Patients, normal controls and blood sampling
Complement assays
Complement activation markers were measured as C3a-desArg (C3a), C5a-des-Arg (C5a), SC5b-9 and Bb fragment (Bb) using commercial enzyme-linked immunosorbent assay (ELISA) (MicroVue kits, Quidel Corp, from Pathway Diagnostics Ltd, Dorking, UK). Samples from each patient were tested on the same ELISA plate. The intra-and inter-assay coefficient of variation (CV) was as follows: C3a 1.8% and 3.4%; C5a 1.9% and 2.4%; SC5b-9 2.0% and 2.6%; Bb 1.9% and 2.7%, respectively.
International Normalised Ratio and rivaroxaban levels
International Normalised Ratio (INR) values were measured using PT Fib HS Plus on a TOP500 (Werfen, Warrington, UK), using an analyser specific ISI in the two groups of patients on warfarin. Rivaroxaban levels were measured in 55 patients receiving rivaroxaban on day 42 using an amidolytic anti-Xa assay (Biophen DiXaI; Hyphen BioMed, Neuville-Sur-Oise, France).
Statistical analysis
There were no suitable data on which to base power calculations; this was a pilot study based on the samples available from the RAPS trial. Data analysis was performed using 
Complement activation markers
The normal reference ranges, as measured in the 55 NC, for C3a, C5a, SC5b-9 and Bb fragment were: 27-96 ng/mL, 0.8-13.0 ng/mL, 60-164 ng/mL and 0.7-1.7 µg/mL, respectively. APS patients had significantly higher median complement activation markers compared with NC at both baseline and day 42, irrespective of the anticoagulant (p<0.0001
for C3a, C5a, SC5b-9 and Bb fragment; Fig. 1-4 ). At baseline (when all patients were on warfarin), there were no differences between the two patient groups for these markers and there were no differences at day 42 in those who remained on warfarin. C3a, C5a, SC5b-9
and Bb were elevated in 42 (38%), 44 (40%), 80 (72%) and 33 (30%) of the 111 patients, respectively.
Increased C3a, C5a, SC5b-9 and Bb fragment levels were not associated with the presence of triple positivity for aPL, or with the presence of LA. Furthermore, no significant differences were observed in the complement activation markers between patients with primary APS and those with SLE-associated APS on warfarin or rivaroxaban. Increased complement activation markers were not associated with higher or lower INR values. The 55 patients randomised to receive rivaroxaban displayed significantly lower median C3a, C5a and SC5b-9 on day 42 (levels on day 42, compared to baseline levels on warfarin ( Fig. 1B-3B There were no significant correlations between rivaroxaban levels and C3a, C5a, SC5b-9, or
Bb fragment levels and there were no significant associations between higher or lower rivaroxaban concentrations (top and bottom tertiles 190-461 and 50-138ng/ml, respectively) and elevated complement markers.
Discussion
This study demonstrates, in the context of the RAPS RCT, that APS patients with previous VTE treated with warfarin exhibit significantly increased complement activation compared with NC, in agreement with previous studies [14 ;16] . The mechanism of this and which pathway is involved is unclear (activation could occur through the classical, lectin, or alternative pathways), since C3a, C5a, SC5b-9 and Bb fragment were all elevated. The novel observation in this study is that this complement activationis significantly decreased by administration of rivaroxaban, a direct FXa inhibitor. Our data indicate that the limiting effect of rivaroxaban on complement activation is likely to occur via the classical pathway as patients treated with rivaroxaban had significantly lower anaphylatoxins (C3a and C5a) and
terminal complement component (SC5b-9), with Bb fragment (a marker of alternative pathway activation) unchanged. We did not measure specific markers of the lectin pathway;
however, preliminary evidence from Breen et al suggests a lack of association of the lectin pathway and complement activation in patients with aPL [34] . There were no correlations between rivaroxaban levels and C3a, C5a, SC5b-9 and Bb fragment levels.
In this study, increased C3a, C5a, SC5b-9 and Bb fragment levels were not associated with the presence of triple positivity for aPL or LA and no significant differences in complement activation marker levels were observed between patients with primary APS and those with SLE-associated APS. Other studies have also reported significantly increased levels of complement activation markers in APS patients compared to NC [14;16] [35] also found increased levels of C3a in patients with aPL, but used citrate rather than EDTA plasma samples, which may result in higher levels of C3a and other markers due to in vitro complement activation. Overall, the clinical studies, including our observations and animal data support the hypothesis that complement activation may play a major role in the pathogenesis of APS [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
The mechanism of rivaroxaban-induced inhibition of complement activation is unknown but may be related to its FXa inhibitory effect; either by direct inhibition of FXa proteolysis and activation of complement proteins, or indirectly by inhibition of pro-inflammatory effects of FXa with downstream complement activation. FXa mediated activation of the complement system in vitro is characterised by physiological (2μg/mL) and supraphysiological FXa levels (20-1002μg/mL), whereas thrombin induced cleavage is observed mainly at supraphysiological thrombin levels [2] . However, these observations were made in the absence of a phospholipid surface and may not apply in vivo. FXa also activates protease activated receptor-1 (PAR-1) and PAR-2 receptors on the vascular endothelium, leading to upregulation of intracellular processes and inflammatory reactions [36] [37] [38] . Heparin which inhibits FXa and thrombin, has inhibitory effects on the production of proinflammatory cytokines from LPS-stimulated monocytes [39] and an anti-inflammatory effect during venous thrombosis [40] , which could contribute to its inhibitory action on complement activation [41;42] . In a mouse model of sickle cell disease, dabigatran, a direct thrombin inhibitor, and rivaroxaban have been demonstrated to reduce both systemic and local inflammatory responses through inhibition of thrombin and FXa respectively [43] . However, translation of the results from mouse models to humans is limited because of differences in the coagulation and complement systems and also their regulation [44] .
The differences in C3a, C5a and SC5b-9 levels, but not Bb fragment, between APS patients treated with rivaroxaban or warfarin could be due to variation in the degree of activation of the AP and CP. Although patients treated with rivaroxaban had significantly lower complement activation markers compared to patients treated with warfarin, both patient groups had complement activation marker levels significantly above those of the NC.
The lack of correlation observed between complement activation markers and rivaroxaban levels, or INR (in warfarin-treated patients), suggests that the effects on complement activation were not related to the intensity of anticoagulation.
In this study, complement activation was tested when peak rivaroxaban concentrations were expected, with maximal inhibition of factor Xa, however some patients had rivaroxaban levels lower than expected (<160 ng/mL) at 2-4 hours after the last rivaroxaban dose (based on population pharmacokinetics studies) [45] . Patients with lower rivaroxaban levels did not have significant differences in C3a, C5a and SC5b-9 levels compared to those with expected therapeutic (or higher) rivaroxaban levels, suggesting that patients treated with rivaroxaban have stable inhibition of complement activation. Furthermore, complement activation markers have short half lives (C5a ~1min, C3a a few hours, SC5b-9 50-60min) [12;46;47] therefore, complement activation is likely to involve a chronic, continuous mechanism. Since warfarin affects the post-translational maturation of FX, reducing plasma FX levels and decreasing its ability to bind phospholipid surfaces, it may not be able to abolish complement activation, whereas rivaroxaban being a small, high affinity,
direct FXa inhibitor is able to be more effective.
Rivaroxaban, as well as being efficacious, safe and convenient, is fixed dose with predictable effect (so that routine anticoagulant monitoring is not required), and has fewer drug interactions than warfarin. Results of the RAPS trial (completed) and other clinical studies (ongoing) [48] [49] [50] will provide more robust information on the role of rivaroxaban and other DOACs in patients with thrombotic APS, and put into context anecdotal case reports and small case series of recurrent thrombosis after switching APS patients from warfarin to a DOAC [51] [52] [53] [54] . Rivaroxaban significantly reduced complement activation compared to warfarin, with an absolute mean reduction in C5a of 32% and in SC5b-9 of 25%. Although complement activation was not restored to normal levels, it is biologically plausible that an inhibitory effect of rivaroxaban on complement activation may potentially provide benefit additional or adjunctive to its anticoagulant effect in patients with APS. Such an effect of rivaroxaban in preventing complement activation might also have wider applicability in other thrombotic states associated with complement activation, such as PNH, where VTE is the main cause of mortality, accounting for 40-67% of PNH-related deaths [11] . When such patients require long-term anticoagulation, the use of rivaroxaban may be valuable in restricting overall complement activation in addition to its anticoagulant effect. The limitations of this study are that: complement activation markers were only assessed at a single time point in each patient and the degree of activation may vary with time; and we did not use assays that discriminate between classical and lectin pathway activation. Future, in vitro studies are required to confirm the route of complement activation in APS, the role of FXa and the mechanism of reduction of complement activation by FXa inhibitors.
In conclusion, we describe the novel observation that rivaroxaban limits complement activation in APS patients with previous VTE compared with warfarin. This action of rivaroxaban is likely to occur via the classical pathway as patients treated with rivaroxaban had significantly lower anaphylatoxins (C3a and C5a) and terminal complement component (SC5b-9), but Bb fragment (a marker of alternative pathway activation) was unchanged. The observations in rivaroxaban-treated patients may reflect inhibition of factor Xa cleavage of complement proteins, or inhibition of its pro-inflammatory effects (and consequent complement activation). Rivaroxaban may therefore potentially provide benefit additional to its anticoagulant effect in this patient group by limiting complement activation.
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Figure 1
Comparison of C3a levels in patients randomised to remain on warfarin (A) or to switch to rivaroxaban (B), at day 42 compared to their baseline values and with normal controls.
A B Figure 2
Comparison of C5a levels in patients randomised to remain on warfarin (A) or to switch to rivaroxaban (B), at day 42 compared to their baseline values and with normal controls.
A B Figure 3
Comparison of SC5b-9 levels in patients randomised to remain on warfarin (A) or to switch to rivaroxaban (B), at day 42 compared to their baseline values and with normal controls.
A B Figure 4
Comparison of Bb fragment levels in patients randomised to remain on warfarin (A) or to switch to rivaroxaban (B), at day 42 compared to their baseline values and with normal controls.
A B Figure 5
Patients with baseline elevation of C5a (A) or SC5b-9 (B) -effect of rivaroxaban
